stifel - Search News

Stifel, Cytokinetics

Cytokinetics started at buy by Stifel, aficamten highlighted

Stifel has initiated coverage of Cytokinetics (CYTK) with a buy rating, citing its drug aficamten, valuation and upcoming catalysts. Read more here.

Fintel on MSN · 11h

Stifel Initiates Coverage of Cytokinetics (CYTK) with Buy Recommendation

Fintel reports that on January 22, 2025, Stifel initiated coverage of Cytokinetics (NasdaqGS:CYTK) with a Buy recommendation. Analyst Price Forecast Suggests 85.04% Upside As of December 23, 2024, the average one-year price target for Cytokinetics is $84.

Investing.com on MSN · 1d

Stifel starts Cytokinetics stock with Buy, $80 target

Stifel analysts initiated coverage on Cytokinetics shares (NASDAQ:CYTK), assigning a Buy rating and setting a price target of $80.00. The new coverage comes after a period of instability for the company,

Stifel Financial Schedules Fourth Quarter & Full Year 2024 Financial Results Conference Call

Stifel Financial Corp. (NYSE: SF) will release its fourth quarter and full year 2024 financial results before the market opens on Wednesday, January 29, 2025. The company will host a conference call ...

6hon MSN

Stifel maintains Buy on Revolve stock with $41 target

Stifel analysts kept a Buy rating on Revolve Group (NYSE:RVLV) shares, maintaining a $41.00 price target. The firm is ...

Hosted on MSN4h

Deregulation will help growth and tap down inflation, Stifel CEO says

Stifel CEO Ron Kruszewski discusses deregulation, economic growth, his expectations for the Federal Reserve handling of rates ...

bovnews1h

Canoo Inc (GOEV) Stock Settles at $0.37: What’s Contributing to This Price Point?

On Tuesday, Canoo Inc (GOEV) stock saw a decline, ending the day at $0.37 which represents a decrease of $-0.98 or -72.59% from the prior close of $1.35. The stock opened at $0.39 and touched a low of ...

Fastenal price target lowered to $82 from $86 at Stifel

Stifel lowered the firm’s price target on Fastenal (FAST) to $82 from $86 and keeps a Hold rating on the shares. Despite the ...

Canada’s Eight Capital to Shut Down as Stifel Swoops In for Bankers

Canadian investment dealer Eight Capital Corp. is winding down and many of its top staff are headed to Stifel Financial Corp.

Take-Two price target raised to $223 from $220 at Stifel

Stifel analyst Drew Crum raised the firm’s price target on Take-Two (TTWO) to $223 from $220 and keeps a Buy rating on the shares. The firm ...

24/7 Wall St1d

2025 Bull Market: Here's How High These Wall Street Analysts Think the Market Could Go In 2025

Wall Street analysts are buzzing with optimism as we step into 2025. There are plenty of reasons for a positive view to ...

bovnews1d

Why Did Stifel Give Altimmune Inc (ALT) Stock Buy Rating?

Altimmune Inc (ALT) stock saw a modest uptick, ending the day at $6.86 which represents a slight increase of $0.15 or 2.24% from the prior close of $6.71. The stock opened at $6.8 and touched a low of ...